Related Experiment Video

Updated: Aug 20, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Protein kinase C in cardiac disease and as a potential therapeutic target

Stephen Murphy1, William H Frishman

  • 1Department of Internal Medicine, University of Colorado School of Medicine, Denver, CO, USA.

Cardiology in Review
|December 15, 2004
PubMed

Insights

Protein kinase C (PKC) impacts cellular signaling and disease. Targeting PKC offers potential therapeutic strategies for cardiovascular diseases like heart failure and hypertension.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Protein kinase C (PKC) is a crucial family of serine/threonine kinases involved in cellular signaling pathways.
  • PKC plays a significant role in the molecular mechanisms underlying various disease states.
  • Dysregulation of PKC is implicated in the pathogenesis of cardiovascular conditions.

Purpose of the Study:

  • To review the multifaceted roles of Protein Kinase C (PKC) in cardiovascular disease.
  • To explore PKC's involvement in specific cardiovascular conditions including ischemic heart disease, cardiac hypertrophy, heart failure, hypertension, and atherosclerosis.
  • To identify potential therapeutic strategies targeting PKC activity for cardiovascular disease treatment.

Main Methods:

  • Literature review of existing research on PKC and cardiovascular disease.
  • Analysis of signaling cascades governed by PKC in cellular behavior.
  • Synthesis of information on PKC's role in disease pathogenesis.

Main Results:

  • PKC is intricately involved in cellular signaling that governs behavior.
  • PKC plays a significant role in the pathogenesis of numerous diseases.
  • Specific roles of PKC in ischemic heart disease, cardiac hypertrophy, heart failure, hypertension, and atherosclerosis were examined.

Conclusions:

  • Altering PKC function presents a promising avenue for treating various disease states.
  • Targeting PKC activity offers potential for novel therapeutic approaches in cardiovascular medicine.
  • Further research into PKC modulation could lead to effective treatments for cardiovascular disorders.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...